Emma C Gertsen1, Alicia S Borggreve1,2, Hylke J F Brenkman1, Rob H A Verhoeven3,4, Erik Vegt5,6, Richard van Hillegersberg1, Peter D Siersema7, Jelle P Ruurda8,9. 1. Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. 2. Department of Radiation Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. 3. Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands. 4. Department of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands. 5. Department of Radiology and Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands. 6. Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 7. Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands. 8. Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. J.P.Ruurda@umcutrecht.nl. 9. Department of Surgery, Division Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands. J.P.Ruurda@umcutrecht.nl.
Abstract
BACKGROUND: The role of 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET/CT) and staging laparoscopy (SL) has increased in the preoperative staging of gastric cancer. Dutch national guidelines have recommended the use of FDG-PET/CT and SL for patients with locally advanced tumors since July 2016. OBJECTIVE: The aim of this study was to evaluate the implementation of FDG-PET/CT and SL in The Netherlands. METHODS: Between 2011 and 2018, all patients who underwent surgery for gastric cancer were included from the Dutch Upper GI Cancer Audit. The use of FDG-PET/CT and SL was evaluated before and after revision of the Dutch guidelines. Outcomes included the number of non-curative procedures (e.g. palliative and futile procedures) and the association of FDG-PET/CT and SL, with waiting times from diagnosis to the start of treatment. RESULTS: A total of 3310 patients were analyzed. After July 2016, the use of FDG-PET/CT (23% vs. 61%; p < 0.001) and SL (21% vs. 58%; p < 0.001) increased. FDG-PET/CT was associated with additional waiting time to neoadjuvant therapy (4 days), as well as primary surgical treatment (20 days), and SL was associated with 8 additional days of waiting time to neoadjuvant therapy. Performing SL or both modalities consecutively in patients in whom it was indicated was not associated with the number of non-curative procedures. CONCLUSION: During implementation of FDG-PET/CT and SL after revision of the guidelines, both have increasingly been used in The Netherlands. The addition of these staging methods was associated with increased waiting time to treatment. The number of non-curative procedures did not differ after performing none, solely one, or both staging modalities.
BACKGROUND: The role of 18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET/CT) and staging laparoscopy (SL) has increased in the preoperative staging of gastric cancer. Dutch national guidelines have recommended the use of FDG-PET/CT and SL for patients with locally advanced tumors since July 2016. OBJECTIVE: The aim of this study was to evaluate the implementation of FDG-PET/CT and SL in The Netherlands. METHODS: Between 2011 and 2018, all patients who underwent surgery for gastric cancer were included from the Dutch Upper GI Cancer Audit. The use of FDG-PET/CT and SL was evaluated before and after revision of the Dutch guidelines. Outcomes included the number of non-curative procedures (e.g. palliative and futile procedures) and the association of FDG-PET/CT and SL, with waiting times from diagnosis to the start of treatment. RESULTS: A total of 3310 patients were analyzed. After July 2016, the use of FDG-PET/CT (23% vs. 61%; p < 0.001) and SL (21% vs. 58%; p < 0.001) increased. FDG-PET/CT was associated with additional waiting time to neoadjuvant therapy (4 days), as well as primary surgical treatment (20 days), and SL was associated with 8 additional days of waiting time to neoadjuvant therapy. Performing SL or both modalities consecutively in patients in whom it was indicated was not associated with the number of non-curative procedures. CONCLUSION: During implementation of FDG-PET/CT and SL after revision of the guidelines, both have increasingly been used in The Netherlands. The addition of these staging methods was associated with increased waiting time to treatment. The number of non-curative procedures did not differ after performing none, solely one, or both staging modalities.
Authors: Linde A D Busweiler; Johan L Dikken; Daniel Henneman; Mark I van Berge Henegouwen; Vincent K Y Ho; Rob A E M Tollenaar; Michel W J M Wouters; Johanna W van Sandick Journal: J Surg Oncol Date: 2017-05-15 Impact factor: 3.454
Authors: L A D Busweiler; B P L Wijnhoven; M I van Berge Henegouwen; D Henneman; N C T van Grieken; M W J M Wouters; R van Hillegersberg; J W van Sandick Journal: Br J Surg Date: 2016-10-05 Impact factor: 6.939
Authors: Salah-Eddin Al-Batran; Nils Homann; Claudia Pauligk; Thorsten O Goetze; Johannes Meiler; Stefan Kasper; Hans-Georg Kopp; Frank Mayer; Georg Martin Haag; Kim Luley; Udo Lindig; Wolff Schmiegel; Michael Pohl; Jan Stoehlmacher; Gunnar Folprecht; Stephan Probst; Nicole Prasnikar; Wolfgang Fischbach; Rolf Mahlberg; Jörg Trojan; Michael Koenigsmann; Uwe M Martens; Peter Thuss-Patience; Matthias Egger; Andreas Block; Volker Heinemann; Gerald Illerhaus; Markus Moehler; Michael Schenk; Frank Kullmann; Dirk M Behringer; Michael Heike; Daniel Pink; Christian Teschendorf; Carmen Löhr; Helga Bernhard; Gunter Schuch; Volker Rethwisch; Ludwig Fischer von Weikersthal; Jörg T Hartmann; Michael Kneba; Severin Daum; Karsten Schulmann; Jörg Weniger; Sebastian Belle; Timo Gaiser; Fuat S Oduncu; Martina Güntner; Wael Hozaeel; Alexander Reichart; Elke Jäger; Thomas Kraus; Stefan Mönig; Wolf O Bechstein; Martin Schuler; Harald Schmalenberg; Ralf D Hofheinz Journal: Lancet Date: 2019-04-11 Impact factor: 79.321
Authors: Elizabeth Smyth; Heiko Schöder; Vivian E Strong; Marinela Capanu; David P Kelsen; Daniel G Coit; Manish A Shah Journal: Cancer Date: 2012-05-01 Impact factor: 6.860
Authors: John M Findlay; Stefan Antonowicz; Ashvina Segaran; Jihene El Kafsi; Alexa Zhang; Kevin M Bradley; Richard S Gillies; Nicholas D Maynard; Mark R Middleton Journal: Eur Radiol Date: 2019-01-14 Impact factor: 5.315